Jazz Pharmaceuticals JAZZ Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other comprehensive income loss cash flow hedge gain loss before reclassification tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other comprehensive income loss cash flow hedge gain loss before reclassification tax?
- Jazz Pharmaceuticals (JAZZ) reported other comprehensive income loss cash flow hedge gain loss before reclassification tax of -$100K in Q1 2026.
- How has Jazz Pharmaceuticals's other comprehensive income loss cash flow hedge gain loss before reclassification tax changed year-over-year?
- Jazz Pharmaceuticals's other comprehensive income loss cash flow hedge gain loss before reclassification tax decreased by 200.0% year-over-year, from $100K to -$100K.
- What does other comprehensive income loss cash flow hedge gain loss before reclassification tax mean?
- The tax impact related to the gains or losses on hedging agreements.
- How do you interpret other comprehensive income loss cash flow hedge gain loss before reclassification tax?
- Provides context on the tax efficiency of the company's hedging strategy and the net impact on shareholder equity.
- How does other comprehensive income loss cash flow hedge gain loss before reclassification tax compare across companies?
- Standard accounting practice; depends on the tax jurisdiction and the nature of the hedge.